The Menopause Society — 2026 Annual Meeting

Menopause Hormone Therapy and Weight Loss Response to GLP-1–Based Therapies in Midlife Women: A Retrospective Cohort Study

At a glance

In this large real-world cohort of midlife women treated for overweight or obesity, concomitant HT was associated with significantly greater and sustained weight loss with SEM. A similar directional effect with TZP was observed at early timepoints but did not reach statistical significance. Larger prospective studies are warranted to confirm these observations and to inform individualized treatment strategies in midlife women.

Background/Objectives

Weight gain during midlife is a common concern among women. While largely driven by aging, menopause-related factors may further contribute to fat accumulation and redistribution. Glucagon-like peptide-1 receptor agonist (GLP-1 RA)–based obesity medications (OM) are effective for weight loss, although treatment response may vary by sex and reproductive stage. Female sex and younger age have been associated with greater weight loss responses to these medications. Likewise, small retrospective observational cohort studies in postmenopausal women suggest that use of menopause hormone therapy (HT) is associated with a greater weight loss response to semaglutide (SEM; GLP-1 RA) and tirzepatide (TZP; a dual GLP-1/glucose-dependent insulinotropic polypeptide [GIP] agonist). Together, these findings support a potential role for ovarian hormones in modulating response to GLP-1 RA–based medications. This study aimed to determine whether weight loss with SEM or TZP differs between midlife women using HT (+HT) and those not using HT (noHT) in a large cohort of women across the menopausal transition and beyond.

Methods

This retrospective observational cohort study included women ≥45 years with a BMI ≥27 kg/m² using SEM or TZP, with or without concomitant HT. Exclusion criteria included <12 months of GLP-1–based therapy, prior bariatric surgery, active malignancy, or concurrent use of other OMs. HT included oral or transdermal estrogen, with or without progesterone. Data from February 2017 to December 2025 were obtained from electronic health records using the nSights federated platform. To mitigate confounding, 1:2 nearest-neighbor propensity score matching without replacement was performed within each cohort, matching each HT user to two nonusers using age, baseline BMI, prior OM use, and type 2 diabetes status, with exact matching on diabetes status and caliper restrictions for age and BMI. The primary outcome was percent total body weight loss (TBWL%) with SEM or TZP at 3, 6, 9, 12, and 15 months, and at last follow-up. Secondary outcomes included the proportion achieving ≥5%, ≥10%, ≥15%, ≥20%, ≥25%, and ≥30% TBWL. Continuous variables are presented as mean (SD) and were compared using Welch’s two-sample t-test, while categorical outcomes were compared using chi-square tests.

Results

The SEM cohort included 2,379 women (n=793 +HT; n=1,586 noHT), with a mean age of 57 years (SD 8) and mean BMI of 36 kg/m² (SD 5). Baseline demographic characteristics and adiposity-related comorbidities were well-balanced among HT users and nonusers. Median follow-up was 26 months (IQR 18–36) in the SEM +HT group and 26 months (IQR 17–37) in the SEM noHT group. Compared with nonuse, HT use was associated with significantly greater TBWL beginning at 9 months (−9.8% vs −8.2%, p<0.001), with differences persisting at 12 months (−11.0% vs −9.5%, p=0.001), 15 months (−11.6% vs −9.7%, p<0.001), and last follow-up (−11.9% vs −10.9%, p=0.020). Women in the +HT group were also more likely to achieve ≥10% (55% vs 51%, p=0.045), ≥20% (22% vs 18%, p=0.037), ≥25% (13% vs 10%, p=0.008), and ≥30% (6% vs 4%, p=0.015) TBWL. The TZP cohort included 1,476 women (n=492 +HT; n=984 noHT), with a mean age of 57 years (SD 7) and mean BMI of 36 kg/m² (SD 5). Baseline demographic characteristics and adiposity-related comorbidities were well-balanced among HT users and nonusers. Median follow-up was 17 months (IQR 12–26) for the TZP +HT group and 16 months (IQR 11–24) for the TZP noHT group. HT use was associated with modestly greater weight loss at 3 months (−6.6% vs −5.9%, p=0.031) and a higher proportion achieving ≥5% TBWL at last follow-up (88% vs 84%, p=0.041); however, no significant differences were observed at later timepoints or for higher weight loss thresholds (all p>0.05).

Conclusions

In this large real-world cohort of midlife women treated for overweight or obesity, concomitant HT was associated with significantly greater and sustained weight loss with SEM. A similar directional effect with TZP was observed at early timepoints but did not reach statistical significance. Larger prospective studies are warranted to confirm these observations and to inform individualized treatment strategies in midlife women.

Publication type and venue follow the original nference listing. Read the original paper for full methods, analyses, and interpretation. View source listing.

Keep exploring.

All publications
CardiometabolismPreprint - Submitted for Peer-Review

Excessive Weight Loss with Zepbound Is Associated with Higher Rates of Adverse Events, Electrolyte Imbalances, and Hospitalization than Moderate Weight Loss

While residual confounding and documentation differences may contribute to some real-world associations, the significantly greater burden of adverse events, hospitalization rates, laboratory test anomalies, and vital-sign abnormalities among Zepbound patients with excessive weight loss warrants further investigation.

Preprints.org
October 21, 2026
Your next question could change everything.

What will you
discover next?

Let’s find out
Ideas are connected. Your next discovery starts here.